Oncimmune (LON:ONC) Announces Quarterly Earnings Results

Oncimmune (LON:ONC) released its quarterly earnings data on Monday. The company reported GBX (4.72) (($0.06)) EPS for the quarter, Digital Look Earnings reports. Oncimmune had a negative return on equity of 760.96% and a net margin of 586.08%.

Oncimmune Price Performance

LON ONC opened at GBX 8.65 ($0.11) on Tuesday. Oncimmune has a one year low of GBX 8 ($0.10) and a one year high of GBX 31 ($0.38). The stock has a 50-day moving average of GBX 13.48 and a 200 day moving average of GBX 14.81. The company has a market capitalization of £6.41 million, a price-to-earnings ratio of -288.33 and a beta of 1.19. The company has a debt-to-equity ratio of 806.85, a quick ratio of 0.63 and a current ratio of 1.13.

Oncimmune Company Profile

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.